Catalyst Event

Eli Lilly and Co (LLY) · Other

From KEDI U.S. Quality500 + Monthly 1% Premium Index(NTR) (KUSQL500P)

6/9/2026, 12:00:00 AM

OtherSentiment: Positive

The FDA approved an extended, every-8-weeks maintenance dosing for Eli Lilly's drug EBGLYSS for atopic dermatitis.

Korean Translation

FDA가 아토피 피부염 치료제 EBGLYSS에 대해 8주 간격의 유지 요법을 승인함.

Related Recent Events

View Full Timeline